3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
3
Recruiting
2
Active not recruiting
1
Sponsor Class
OTHER
2
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Thoracic
8
Other solid neoplasm
4
Gastrointestinal
3
Sarcoma
2
NET
2
Head & Neck
2
Gynecologic
2
Endocrine
2
Dermatologic
2
CNS
2
Plasma cell
1
Other hematologic neoplasm
1
Genitourinary
1
Breast
1
Conditions
Neuroendocrine Tumors
111
Gastro-enteropancreatic neuroendocrine tumor
19
Carcinoma, Neuroendocrine
12
Stomach Neoplasms
11
Pancreatic Neoplasms
10
Neoplasms
10
Breast Neoplasms
10
Pheochromocytoma
9
Carcinoid Tumor
9
Prostatic Neoplasms
8
Paraganglioma
8
Neoplasm Metastasis
8
Carcinoma, Hepatocellular
8
Adenoma, Islet Cell
8
Thyroid Neoplasms
7
Sarcoma
7
Gastrointestinal Neoplasms
7
Esophageal Neoplasms
7
Colorectal Neoplasms
7
Lung Neoplasms
6
Rectal Neoplasms
5
Ovarian Neoplasms
5
Neuroblastoma
5
Melanoma
5
Liver Neoplasms
5
Colonic Neoplasms
5
Anus Neoplasms
5
Uterine Cervical Neoplasms
4
Gastrointestinal Stromal Tumors
4
Cholangiocarcinoma
4
Interventions
Everolimus
1
177Lu-octreotide, DOTA(0)-Tyr(3)-
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recruiting
×
Thymus Neoplasms
×
NET
×
Clear all
NCT05918302
2026-05-12
LEVEL
Grupo Espanol de Tumores Neuroendocrinos
Phase 3
Recruiting
170 enrolled
NCT02012699
2026-05-05
iCaRe2
University of Nebraska
Recruiting
999,999 enrolled